{
    "nctId": "NCT06338605",
    "briefTitle": "Evaluating the Incidence of Pseudo-Acute Kidney Injuries in Patients With Metastatic Breast Cancer on CDK4/6 Inhibitors Trough Cystatin C Analysis",
    "officialTitle": "Evaluating the Incidence of Pseudo-Acute Kidney Injuries in Patients With Metastatic Breast Cancer on CDK4/6 Inhibitors Trough Cystatin C Analysis",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Advanced Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Pseudo-AKI in patients on CDK4/6 inhibitors",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patients who are receiving CDK4/6 inhibitors for metastatic breast cancer\n* Patients must have used the CDK4/6 inhibitor for a minimum duration of one month\n* Patients must have undergone at least one measurement of creatinine after the initiation of CDK4/6 inhibitor treatment\n\nExclusion Criteria:\n\n- Patients who are undergoing dialysis therapy for kidney failure.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}